Gastro One

Cordova, Tennessee 38018

3 studies enrolling now · 12 studies all time

What they study most

Cirrhosis, Liver, Colorectal Cancer, Fibrostenotic Crohn's Disease, Heartburn, Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, NASH, Non-Erosive Gastro-Esophageal Reflux Disease, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Ulcerative Colitis

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
• A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. — Running, not enrolling
• Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC — Completed
• STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease — Completed
• A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
• Stool Sample Collection Study — Status unconfirmed
• A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) — Completed